https://investorshub.advfn.com/stock-market/NASDAQ/briacell-therapeutics-BCTX/stock-news/97694162/briacell-highlights-extended-18-47-months-surviva BriaCell is not about chasing a couple of extra months of PFS. It is about long-tail survival — where some patients live years instead of months. That profile naturally prolongs trials, blurs short-term forecasts, but is exactly how real oncology blockbusters are born. Ultimately, the most meaningful validation would be the entry of a major pharmaceutical player as a strategic partner or shareholder. The data look good… but somehow, never a moment of joy.
Market Data 
Markets 
AI
